184 related articles for article (PubMed ID: 9226461)
1. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
[TBL] [Abstract][Full Text] [Related]
2. Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
J Atheroscler Thromb; 2000; 7(2):110-21. PubMed ID: 11426582
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
[TBL] [Abstract][Full Text] [Related]
4. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
Sasaki J; Arakawa K; Iwashita M; Matsushita Y; Kono S;
Circ J; 2003 Jun; 67(6):473-8. PubMed ID: 12808261
[TBL] [Abstract][Full Text] [Related]
5. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
[TBL] [Abstract][Full Text] [Related]
6. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
8. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
[TBL] [Abstract][Full Text] [Related]
10. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
Sasaki S; Nakagawa M; Nakata T; Azuma A; Sawada S; Takeda K; Asayama J;
Circ J; 2002 Jan; 66(1):47-52. PubMed ID: 11999665
[TBL] [Abstract][Full Text] [Related]
11. [Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Itakura H
Nihon Rinsho; 2002 May; 60(5):889-98. PubMed ID: 12029990
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
[TBL] [Abstract][Full Text] [Related]
13. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
[TBL] [Abstract][Full Text] [Related]
15. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
Eriksson M; Hådell K; Holme I; Walldius G; Kjellström T
J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study.
Saito Y; Shirai K; Sasaki N; Shinomiya M; Yoshida S;
J Atheroscler Thromb; 2002; 9(2):99-108. PubMed ID: 12236319
[TBL] [Abstract][Full Text] [Related]
17. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group.
J Clin Epidemiol; 1992 Aug; 45(8):849-60. PubMed ID: 1624967
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
19. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
Shepherd J; Gaw A;
Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
[TBL] [Abstract][Full Text] [Related]
20. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Shepherd J
Am J Cardiol; 1995 Sep; 76(9):113C-117C. PubMed ID: 7572679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
